Reduced EOM volume is one of the hallmarks of teprotumumab treatment, leading to decreased proptosis and improved motility and diplopia (91–93), and it has also been observed in a proof-of-concept RCT with batoclimab, an inhibitor of the neonatal fragment crystallizable receptor (FcRn) (94). The gene discussed is FCGRT; the disease is Diplopia.